The chemoradiation paradigm in head and neck cancer

Tanguy Lim Seiwert, Joseph K. Salama, Everett E. Vokes

Research output: Contribution to journalReview article

Abstract

In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success. The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing toxic effects are increasingly the focus of clinical trials. We review the available chemoradiotherapy platforms used for head and neck cancer, with initial discussions focused on single-agent cytotoxic-based regimens. We then assess the literature on multiagent-based regimens and include a discussion of the integration of novel agents, such as EGFR inhibitors, and antiangiogenic drugs into treatment platforms. Although single-agent cisplatin-based chemoradiotherapy is still widely used as a standard therapy, we propose that evidence increasingly shows that multiagent-based chemoradiotherapy, and EGFR-inhibitor-based treatments, offer distinct advantages. We provide guidance for clinicians based on current clinical trial evidence on how to choose appropriate treatment platforms for their patients.

Original languageEnglish (US)
Pages (from-to)156-171
Number of pages16
JournalNature Clinical Practice Oncology
Volume4
Issue number3
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Chemoradiotherapy
Clinical Trials
Therapeutics
Poisons
Cytotoxins
Cisplatin
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

The chemoradiation paradigm in head and neck cancer. / Lim Seiwert, Tanguy; Salama, Joseph K.; Vokes, Everett E.

In: Nature Clinical Practice Oncology, Vol. 4, No. 3, 01.03.2007, p. 156-171.

Research output: Contribution to journalReview article

Lim Seiwert, Tanguy ; Salama, Joseph K. ; Vokes, Everett E. / The chemoradiation paradigm in head and neck cancer. In: Nature Clinical Practice Oncology. 2007 ; Vol. 4, No. 3. pp. 156-171.
@article{8792e53515ee45b8a78993b26ee71986,
title = "The chemoradiation paradigm in head and neck cancer",
abstract = "In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success. The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing toxic effects are increasingly the focus of clinical trials. We review the available chemoradiotherapy platforms used for head and neck cancer, with initial discussions focused on single-agent cytotoxic-based regimens. We then assess the literature on multiagent-based regimens and include a discussion of the integration of novel agents, such as EGFR inhibitors, and antiangiogenic drugs into treatment platforms. Although single-agent cisplatin-based chemoradiotherapy is still widely used as a standard therapy, we propose that evidence increasingly shows that multiagent-based chemoradiotherapy, and EGFR-inhibitor-based treatments, offer distinct advantages. We provide guidance for clinicians based on current clinical trial evidence on how to choose appropriate treatment platforms for their patients.",
author = "{Lim Seiwert}, Tanguy and Salama, {Joseph K.} and Vokes, {Everett E.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1038/ncponc0750",
language = "English (US)",
volume = "4",
pages = "156--171",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The chemoradiation paradigm in head and neck cancer

AU - Lim Seiwert, Tanguy

AU - Salama, Joseph K.

AU - Vokes, Everett E.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success. The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing toxic effects are increasingly the focus of clinical trials. We review the available chemoradiotherapy platforms used for head and neck cancer, with initial discussions focused on single-agent cytotoxic-based regimens. We then assess the literature on multiagent-based regimens and include a discussion of the integration of novel agents, such as EGFR inhibitors, and antiangiogenic drugs into treatment platforms. Although single-agent cisplatin-based chemoradiotherapy is still widely used as a standard therapy, we propose that evidence increasingly shows that multiagent-based chemoradiotherapy, and EGFR-inhibitor-based treatments, offer distinct advantages. We provide guidance for clinicians based on current clinical trial evidence on how to choose appropriate treatment platforms for their patients.

AB - In this article, we use the example of head and neck cancer to show how concurrent chemoradiotherapy is used to treat a cancer where locoregional control is central for treatment success. The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing toxic effects are increasingly the focus of clinical trials. We review the available chemoradiotherapy platforms used for head and neck cancer, with initial discussions focused on single-agent cytotoxic-based regimens. We then assess the literature on multiagent-based regimens and include a discussion of the integration of novel agents, such as EGFR inhibitors, and antiangiogenic drugs into treatment platforms. Although single-agent cisplatin-based chemoradiotherapy is still widely used as a standard therapy, we propose that evidence increasingly shows that multiagent-based chemoradiotherapy, and EGFR-inhibitor-based treatments, offer distinct advantages. We provide guidance for clinicians based on current clinical trial evidence on how to choose appropriate treatment platforms for their patients.

UR - http://www.scopus.com/inward/record.url?scp=33847653707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847653707&partnerID=8YFLogxK

U2 - 10.1038/ncponc0750

DO - 10.1038/ncponc0750

M3 - Review article

C2 - 17327856

AN - SCOPUS:33847653707

VL - 4

SP - 156

EP - 171

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 3

ER -